Skip to content
ppharmaranks
Menu
Class IIOngoing

Icosapent Ethyl Capsules recall

FDA recall D-0400-2026 · initiated Mar 9, 2026

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Mar 18, 2026How we research

Zydus Pharmaceuticals (USA) Inc recalled Icosapent Ethyl Capsules in Mar 2026 — an FDA Class II recall (D-0400-2026) because Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient.

The manufacturing process itself

The FDA found the process itself out of compliance, usually before any defective product was identified.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot #: S2520249, S2520250, S2520267, Exp. Date 2027/Jan; S2520303, S2520305, S2520332, Exp. Date 2027/Feb; S2540208, S2540209, Exp. Date 2027/Apr

Quantity recalled: 60,541 bottles

Details

Product
Icosapent Ethyl Capsules, 1 gram, 120 Capsules per bottle, Rx only, Manufactured by: Softgel Healthcare Pvt. Ltd., India; Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534. NDC: 70710-1592-7
Recalling company
Zydus Pharms
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
Nationwide in the USA
Initiated
Mar 9, 2026
FDA report date
Mar 18, 2026
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Icosapent Ethyl Capsules recalled?
Zydus Pharmaceuticals (USA) Inc recalled Icosapent Ethyl Capsules in Mar 2026 — an FDA Class II recall (D-0400-2026) because Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Icosapent Ethyl Capsules recalled?
Per the FDA enforcement record, the reason for recall D-0400-2026 was: Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient.
Is a recalled Icosapent Ethyl Capsules dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Icosapent Ethyl Capsules are affected?
Distributed: Nationwide in the USA. The recall covers these lots — Lot #: S2520249, S2520250, S2520267, Exp. Date 2027/Jan; S2520303, S2520305, S2520332, Exp. Date 2027/Feb; S2540208, S2540209, Exp. Date 2027/Apr. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0400-2026.

Source: openFDA Drug Enforcement record D-0400-2026

← All drug recalls